Table 1.
Menin Inhibitors in Clinical Trials. Note: Aza, azacitidine; KMT2Ar histone-lysine-N-methyltransferase 2 rearranged; mini-HCV lower intensity cyclophosphamide, vincristine, doxorubicin and dexamethasone; R/R, relapsed or refractory; ven, venetoclax.
| Molecule | Phase | Enrollment | Status | Regimen | NCT | Population |
|---|---|---|---|---|---|---|
| SNDX-5613 | I/II | 186 | Recruiting | Monotherapy | NCT04065399 | Relapsed/refractory (R/R) MPAL, KMT2Ar AML, NPM1m AML |
| KO-539 | I/II | 100 | Recruiting | Monotherapy | NCT04067336 | Relapsed/refractory all patients expansion: KMT2Ar and NPM1m R/R AML [57] |
| JNJ-75276617 | I | 110 | Recruiting | Monotherapy | NCT04811560 | Relapsed/refractory: KMT2Ar, NPM1m AML |
| BMF-219 | I/II | 100 | Recruiting | Monotherapy | NCT05153330 | Relapsed/refractory all patients (with and without strong CYP3A4 inhibitors) |
| DS-1594b | I/II | 122 | Recruiting | Combination (ven/aza or Mini-HCV) |
NCT04752163 | Monotherapy in relapsed/Refractory KMT2Ar AML Monotherapy in relapsed/Refractory NPM1m AML Aza/Ven Combo in R/R NPM1 or KMT2Ar AML Mini-HCVD in R/R ALL with KMT2Ar |